ABSTRACT

In the latest years, high quantities of biomarkers have been studied in Asthma and Chronic Obstructive Pulmonary Disease (COPD). A good biomarker should have the following characteristics: 1) clinical relevance, sensibility and specificity, c) reliability and reproducibility, d) easy to measure and to obtain. The samples in which the biomarkers can be determined are from different sources (lung biopsy, bronchoalveolar lavage, sputum, exhaled breath, urine, and blood). The biomarkers can offer complementary information in order to achieve diagnosis, stage, progression, and disease activity as well as response to treatment. In this report, we review the principal reports on biomarkers in asthma and COPD. A search for articles published between the years 1989-2013 using the Medline database. In this article we review the main biomarkers in asthma and COPD.

KEYWORDS

Biomarkers, asthma, COPD, treatment.

REFERENCES

1. Dasgupta A, Nair P. When are biomarkers useful in the management of airway diseases? Pol Arch Med Wewn 2013;123:183-188.

2. Lesko LJ, Atkinson AJ Jr. Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies. Annu Rev Pharmacol Toxicol 2001;41:347-366.

3. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular approaches. Nat Med 2012;18:716-725.

4. O’Byrne PM. Global guidelines for asthma management: summary of the current status and future challenges. Pol Arch Med Wewn 2010;120:511-517.

5. Disponible en: http://www.ginasthma.org/uploads/users/files/GINA Fecha de consulta: abril 2011.

6. Decramer M, Janssens W, Miravitlles M. Chronic obstructive pulmonary disease. Lancet 2012;379:1341-1351.

7. Disponible en: http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf

8. Taylor DR, Pavord ID. Biomarkers in the assessment and management of airways diseases. Postgrad Med J 2008;84:628-634.

9. Patel AR, Hurst JR, Wedzicha JA. The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. Semin Respir Crit Care Med 2010;31:267-275.

10. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011;184:662-671.

11. Hurst J. Phenotype-based care in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:935-936.

12. Pinto-Plata V, Casanova C, Müllerova H, et al. Inflammatory and repair serum biomarker pattern: association to clinical outcomes in COPD. Respir Res 2012;13:71.

13. Smith AD, Cowan JO, Filsell S, et al. Diagnosing asthma: comparisons between exhaled nitric oxide measurements and conventional tests. Am J Respir Crit Care Med 2004;169:473-478.

14. Bommarito L, Migliore E, Bugiani M, et al. Exhaled nitric oxide in a population sample of adults. Respiration 2008;75:386-392.

15. Dweik RA, Boggs PB, Erzurum SC, et al.; American Thoracic Society Committee on Interpretation of Exhaled Nitric Oxide Levels (FENO) for Clinical Applications. An official ATS clinical practice guideline: interpretation of exhaled nitric oxide levels (FENO) for clinical applications. Am J Respir Crit Care Med 2011;184:602-615.

16. Pike K, Selby A, Price S, et al. Exhaled nitric oxide monitoring does not reduce exacerbation frequency or inhaled corticosteroid dose in paediatric asthma: a randomised controlled trial. Clin Respir J 2012;doi:10.1111/j.

17. Jartti T, Wendelin-Saarenhovi M, Heinonen I, Hartiala J, Vanto T. Childhood asthma management guided by repeated FeNO measurements: a meta-analysis. Paediatr Respir Rev 2012;13:178-183.

18. Zeiger RS, Schatz M, Zhang F, et al. Association of exhaled nitric oxide to asthma burden in asthmatics on inhaled corticosteroids. J Asthma 2011;48:8-17.

19. Hillas G, Kostikas K, Mantzouranis K, et al. Exhaled nitric oxide and exhaled breath condensate pH as predictors of sputum cell counts in optimally treated asthmatic smokers. Respirology 2011;16:811-818.

20. Bazeghi N, Gerds TA, Budtz-Jørgensen E, Hove J, Vestbo J. Exhaled nitric oxide measure using multiple flows in clinically relevant subgroups of COPD. Respir Med 2011;105:1338-1344.

21. Antus B, Barta I, Horvath I, Csiszer E. Relationship between exhaled nitric oxide and treatment response in COPD patients with exacerbations. Respirology 2010;15:472-477.

22. Kersul AL, Iglesias A, Ríos Á, et al. Molecular mechanisms of inflammation during exacerbations of chronic obstructive pulmonary disease. Arch Bronconeumol 2011;47:176-183.

23. Cai C, Yang J, Hu S, Zhow M, Guo W. Relationship between urinary cysteinyl leukotriene E4 levels and clinical response to antileukotriene treatment in patients with asthma. Lung 2007;185:105-112.

24. Rabinovitch N, Zhang L, Gelfand EW. Urine leukotriene E4 levels are associated with decreased pulmonary function in children with persistent airway obstruction. J Allergy Clin Immunol 2006;118:635-640.

25. Jayaram L, Pizzichini MM, Cook RJ, et al. Determining asthma treatment by monitoring sputum cell counts: effect on exacerbations. Eur Respir J 2006;27:483-494.

26. Gibson PG, Simpson JL, Hankin R, Powell H, Henry RL. Relationship between induced sputum eosinophils and the clinical pattern of childhood asthma. Thorax 2003;58:116-121.

27. Fleming L, Wilson N, Regamey N, Bush A. Use of sputum eosinophil counts to guide management in children with severe asthma. Thorax 2012;67:193-198.

28. Kim S, Nadel JA. Role of neutrophils in mucus hypersecretion in COPD and implications for therapy. Treat Respir Med 2004;3:147-159.

29. Pavord ID, Pizzichini MM, Pizzichini E, Hargreave FE. The use of induced sputum to investigate airway inflammation. Thorax 1997;52:498-501.

30. Hoffmeyer F, Raulf-Heimsoth M, Brüning T. Exhaled breath condensate and airway inflammation. Curr Opin Allergy Clin Immunol 2009;9:16-22.

31. Accordino R, Visentin A, Bordin A, et al. Long-term repeatability of exhaled breath condensate pH in asthma. Respiratory Med 2008;102:377-381.

32. Carraro S, Giordano G, Reniero F, et al. Asthma severity in childhood and metabolomic profiling of breath condensate. Allergy 2013;68:110-117.

33. Warwick G, Thomas PS, Yates DH. Non-invasive biomarkers in exacerbations of obstructive lung disease. Respirology 2013;18:874-884.

34. Takayama G, Arima K, Kanaji T, et al. Periostin: A novel component of subepithelial fibrosis of bronchial asthma downstream of IL-4 and IL-13 signals. J Allergy Clin Immunol 2006;118:98-104.

35. Jia G, Erickson RW, Choy DF, et al; Bronchoscopic Exploratory Research Study of Biomarkers in Corticosteroid-refractory Asthma (BOBCAT) Study Group. Periostin is a systemic biomarker of eosinophilic airway inflammation in asthmatic patients. J Allergy Clin Immunol 2012;130:647-654.

36. Dahl M, Vestbo J, Lange P, et al. C-reactive protein as a predictor of prognosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:250-255.

37. De Torres JP, Pinto-Plata V, Casanova C, et al. C-reactive protein levels and survival in patients with moderate to very severe COPD. Chest 2008;133:1336-1343.

38. Hurst JR, Donaldson GC, Perera WR, et al. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2006;174:867-874.

39. Deraz TE, Kamel TB, El-Kerdany TA, El-Ghazoly HM. High-sensitivity C reactive protein as a biomarker for grading of childhood asthma in relation to clinical classification, induced sputum cellularity, and spirometry. Pediatr Pulmonol 2012;47:220-225.

40. Kishimoto T. The biology of interleukin-6. Blood 1989;74:1-10.

41. Rincon M, Irvin CG. Role of IL-6 in asthma and other inflammatory pulmonary diseases. Int J Biol Sci 2012;8:1281-1290.

42. Bucchioni E, Kharitonov SA, Allegra L, Barnes PJ. High levels of interleukin-6 in the exhaled breath condensate of patients with COPD. Respir Med 2003;97:1299-1302.

43. Djoba-Siawaya JF, Roberts T, Babb C, et al. An evaluation of commercial fluorescent bead-based luminex cytokine assays. PLoS One. 2008;3:e2535.

44. Dahl M, Tybjaerg-Hansen A, Vestbo J, Lange P, Nordestgaard BG. Elevated plasma fibrinogen associated with reduced pulmonary function and increased risk of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001;164:1008-1011.

45. Thomsen M, Dahl M, Lange P, Vestbo J, Nordestgaard BG. Inflammatory biomarkers and comorbidities in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2012;186:982-988.

46. Groenewegen KH, Postma DS, Hop WC, et al. COSMIC Study Group. Increased systemic inflammation is a risk factor for COPD exacerbations. Chest 2008;133:350-357.

47. Fibrinogen Studies Collaboration, Danesh J, Lewington S, Thompson SG, et al. Plasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: an individual participant meta-analysis. JAMA 2005;294:1799-1809.

48. Broeckaert F, Clippe A, Knoops B, Hermans C, Bernard A. Clara cell secretory protein (CC16): features as a peripheral lung biomarker. Ann N Y Acad Sci 2000;923:68-77.

49. Lakind JS, Holgate ST, Ownby DR, et al. A critical review of the use of Clara cell secretory protein (CC16) as a biomarker of acute or chronic pulmonary effects. Biomarkers 2007;12:445-467.

50. Lomas DA, Silverman EK, Edwards LD, et al; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) investigators. Evaluation of serum CC-16 as a biomarker for COPD in the ECLIPSE cohort. Thorax 2008;63:1058-1063.

51. Andreeva AV, Kutuzov MA, Voyno-Yasenetskaya TA. Regulation of surfactant secretion in alveolar type II cells. Am J Physiol Lung Cell Mol Physiol 2007;293:L259-L271.

52. Lomas DA, Silverman EK, Edwards LD, et al. Serum surfactant protein D is steroid sensitive and associated with exacerbations of COPD. Eur Respir J 2009;34:95-102.

53. Sin DD, Leung R, Gan WQ, Man SPBMC. Circulating surfactant protein D as a potential lung-specific biomarker of health outcomes in COPD: a pilot study. BMC Pulm Med 2007;7:13.

54. Foreman MG, Kong X, DeMeo DL, et al. Polymorphisms in surfactant protein-D are associated with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2011;44:316-322.

55. Cheng G, Ueda T, Numao T, et al. Increased levels of surfactant protein A and D in bronchoalveolar lavage fluids in patients with bronchial asthma. Eur Respir J 2000;16:831-835.

56. Bode W. Structural basis of matrix metalloproteinase function. Biochem Soc Symp 2003;(70):1-14.

57. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52:502-506.

58. Higashimoto Y, Yamagata Y, Iwata T, et al. Increased serum concentrations of tissue inhibitor of metalloproteinase-1 in COPD patients. Eur Respir J 2005;25:885-890.

59. Kwiatkowska S, Noweta K, Zieba M, Nowak D, Bialasiewicz p. Enhanced exhalation of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 in patients with COPD exacerbation: a prospective study. Respiration 2012;84:231-241.

60. Foster JA, Curtiss SW. The regulation of lung elastin synthesis. Am J Physiol 1990;259(2 Pt 1):L13-23.

61. Lindberg CA, Engström G, de Verdier MG, et al. Total desmosines in plasma and urine correlate with lung function. Eur Respir J 2012;39:839-845.

62. Huang JT, Chaudhuri R, Albarbarawi O, et al. Clinical validity of plasma and urinary desmosine as biomarkers for chronic obstructive pulmonary disease. Thorax 2012;67:502-508.